Tju Siang Chua

Tju Siang Chua

Auto-generated profile, based on publicly available information

Tju Siang Chua

AliveoMedical Singapore Singapore

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2026 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
SLSomchai Leelakusolvong
Somchai Leelakusolvong
TCTju Siang Chua
Tju Siang Chua
DQDuc Trong Quach
Duc Trong Quach
AOAndrew Ming‐Liang Ong
Andrew Ming‐Liang Ong
ASAri Syam
Ari Syam
Yeong Yeh LeeYeong Yeh Lee
Yeong Yeh Lee
Background and Aim: Proton pump inhibitors (PPIs) are integral to managing many gastrointestinal conditions. However, the prevalent inappropriate PPI prescription across Southeast Asia (SEA) is concerning. Given the absence of locally tailored recommendations to inform clinical practice, this consensus document aims to provide recommendations for PPI rationalization to healthcare providers in the region. Methods: The SEA PPI Rationalization Working Group is steered by 14 experts practicing across Malaysia, Thailand, Singapore, Vietnam, the Philippines, and Indonesia. The experts convened to review existing evidence and develop recommendations and to conduct an anonymous voting as per the modified Delphi method. Results: Twenty statements were formulated, focusing on areas of (i) extent and impact of PPI overprescription (four statements), (ii) benefits and barriers to PPI rationalization (two statements), (iii) START/STOPP criteria for PPI (nine statements), and (iv) PPI rationalization strategies (five statements). The consensus document underscores the widespread inappropriate long‐term PPI prescription across SEA, which may have adverse clinical outcomes. Although rationalizing PPI use may be beneficial, the experts acknowledge the challenges of implementing PPI rationalization. The experts also outlined specific indications to guide PPI initiation and advised regular review to rationalize a PPI when no longer indicated. This is followed by PPI rationalization strategies, including shared decision‐making, prescribing alginate as a rescue therapy in gastroesophageal reflux disease, and further evaluation for reinitiation of PPI when clinically warranted. Conclusions: This consensus document serves to improve PPI prescribing and deprescribing practices in SEA and to provide recommendations on rationalization strategies.

2 June 2026 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
DQDuc Trong Quach
Duc Trong Quach
THTien Manh Huynh
Tien Manh Huynh
AGAugusto Jose G. Galang
Augusto Jose G. Galang
HDHang Viet Dao
Hang Viet Dao
SCSakkarin Chirapongsathorn
Sakkarin Chirapongsathorn
Yeong Yeh LeeYeong Yeh Lee
Yeong Yeh Lee
Despite widespread use, real‐world evidence regarding proton pump inhibitor (PPI) prescribing and rationalization practices in Southeast Asia (SEA) remains limited; therefore, we aimed to characterize current prescribing behaviors and rationalization strategies among healthcare professionals in the region. The SEA PPI Rationalisation Working Group developed and disseminated an online questionnaire via professional networks across SEA to collect data on respondent demographics, PPI prescribing practices, and rationalization approaches; instrument reliability testing produced a Cronbach's α of 0.799 and content validity was confirmed by a panel of 10 gastroenterology experts with complete agreement on relevance and clarity (I‐CVI, kappa, SCVI/Ave = 1.0). K‐mode clustering was applied to delineate prescribing patterns. Of 869 responses received, 763 valid entries were analyzed (response rate 87.8%), 49% of whom were gastroenterologists. PPIs were most frequently prescribed for gastroesophageal reflux disease (67.8%) and peptic ulcer disease (43.8%); 48.9% of respondents reported long‐term PPI use, while 59.2% reported reassessment of indications at every follow‐up visit. Common rationalization strategies comprised dose tapering (46.8%), on‐demand administration (45.9%), and step‐down to antacids or alginates (44.8%). Cluster analysis identified two distinct prescriber profiles: proactive prescribers ( n = 326, 42.7%), who adhered to clinical guidelines, implemented individualized dosing, and routinely reassessed therapy; and conservative prescribers ( n = 437, 57.3%), who employed PPIs more restrictively and engaged less frequently in rationalization. The considerable variability in PPI prescribing and rationalization practices across SEA underscores the need for a regional consensus to promote evidence‐based practice.